Fintel reports that on February 18, 2025, Barclays downgraded their outlook for Moderna (NasdaqGS:MRNA) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 78.68% Upside As of February 18 ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 11.8% in the morning session after it continued to build on the ...

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

Barclays downgraded Moderna (NASDAQ:MRNA) to Equal Weight from Overweight in a note Tuesday, citing policy risks, a lack of major clinical catalysts, and macroeconomic uncertainties that limit the ...

Moderna MRNA announced fourth-quarter 2024 results. Though earnings and sales beat estimates, both metrics declined ...

BofA analyst Tim Anderson lowered the firm’s price target on Moderna (MRNA) to $32 from $34 and keeps an Underperform rating on the shares.

Barclays downgraded Moderna (MRNA) to Equal Weight from Overweight with a price target of $45, down from $111, post the Q4 report. The firm ...